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BIOMEDICAL AND RELATED APPLICATIONS OF SECOND
GENERATION POLYAMIDOAMINES
4Poly(amidoamine)s (PAA) are synthetic polymers containing tert-amine and amide
groups regularly arranged along their polymer chain. They are prepared by
Michael-type polyaddition of amines to bisacrylamides.
Synthetic conditions:
PAAS: INTRODUCTION
Franchini, J.; Ferruti, F. Chapter 16 in Polymeric gene delivery: Principles and Applications., Mansoor M. Amiji, CRC Press, 2005.


































 room temperature, N2 atmosphere, 3 days;
 no catalysts;
 protic solvents (water, alcohols).
5 PAAs are usually water soluble;
 PAAs are polymeric bases of low to medium strength;
 PAAs are biocompatible, biodegradable and non-toxic;
 Easily functionalized with several different functional groups;
 Amphoteric PAAs show stealth properties and EPR effect.
PROPERTIES OF PAAS
Franchini, J.; Ferruti, F. Chapter 16 in Polymeric gene delivery: Principles and Applications., Mansoor M. Amiji, CRC Press, 2005.
Ferruti, P.; Marchisio, M.A.; Duncan, R Macromol. Rapid Commun. 2002, 23, 332.
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ISA23 21500 > 5.00
ISA1 9500 3.05  0.70
POLY-L-LYSINE 56500 0.05  0.01
DEXTRAN 70000 > 5.00
Sample
IC50 (mg/mL)
on Balb/3T3 Clone A31
ISA23 20300 > 5.00
ISA1 14500 2.17  0.75
POLY-L-LYSINE 56500 0.05  0.01
DEXTRAN 70000 > 5.00
Cytoxocity test on B16F10
cell line.
Cytoxocity test on mouse
embryo fibroblasts Balb/3T3






Richardson, S.C.W.; Pattrick, N.G.; Lavignac, N.; Ferruti, P.; Duncan, R. J. Contr. Rel. 2009, 142 (1), 78-88.
Co-localization of ISA1 and ISA23 with lysotracker
Co-localization of ISA1 with EEA1
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PAAS AS CYTOPLASMIC DELIVERY VEHICLES
OF IMMUNOTOXINES
The development and successful application of therapeutic proteins is often
hindered by several difficulties, as for instance insufficient stability and shelf-life,
costly production, immunogenic and allergic potential, as well as poor
bioavailability and sensitivity towards proteases.
To overcome these problems, a possible approach is to modify proteins by
covalently conjugating them with water-soluble polymers, thus increasing their
plasma residence, reducing protein immunogenicity and increasing their
therapeutic index.
Duncan, R. Nat. Rev. Drug Discov. 2003, 2, 214-221.
Duncan, R. Nature Review 2006, 6, 688-701.
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Increasing attention has devoted to the nature of the chemical linkage between the
polymer backbone and protein.
After cell internalization
Ranucci, E.; Ferruti, P.; Suardi, M.A.; Manfredi, A. Macromol. Rapid Commun. 2007, 28, 1243-1250.
Emilitri, E.; Ranucci, E.; Ferruti, P. J. Polym. Sci., Part A: Polym. Chem. 2005, 43, 1404.

















In this work, two PAAs bearing 2-ethenyldithiopyridine pendants were used to





It doesn’t contain the cell-binding
subunit that promotes its internalization
by endocytosis.
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ISA1 18000 30000 1.93 8.67
ISA23 12700 23600 1.86 9.2
Mn Mw













ISA23-SSPy > 5.00 5.00
PEI 0.04  0.01 0.05  0.01
DEXTRAN > 5.00 > 5.00
PAAS AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES
PAA-SSPY CYTOTOXICITY
ISA1-SSPy and ISA23-SSPy were tested by direct contact assay for 72 hours using
B16F10 and Vero cells.
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SUB-CLONING OF GELONIN
PAAS AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES
PAA-SSPy polymers were used to prepare PAA-gelonin complexes in which the
polymeric chain was linked to the bioactive moieties by a disulfide bridge.
To achieve this aim, two types of gelonin were sub-cloned:
6H90 Gelonin 86V5 87 89Gelonin HA 6H
6H-V5-Gelonin Gelonin-HA-Cys-6H
Plasmids encoding both the two protein were made by sub-cloning an open
reading frame coding for gelonin into a commercially available bacterial
expression cassette (pET151/D Topo).
Protein were expressed using BL21(DE3) Competent E. Coli.
16




































1:1000  6XHis Monoclonal Antibody
1:500 Anti-mouse Ig, horseradish whole antibody
6H-V5-Gelonin Gelonin-HA-Cys-6H
























In all further experiments, non toxic concentrations of 6H-V5 Gelonin 
and Gelonin HA-Cys-6H were used.
GELONIN TOXICITY





IC50 : 100 µg/mL. IC50 : 10 µg/mL.
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PAAS AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES
ISA23-SS-GELONIN CONJUGATES: TOXICITY
Cytotoxicity experiments were performed using fixed concentration of protein 
and polymer concentrations up to 2 mg/mL on B16F10 cells.




PAAS AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES
ISA1-SSPy-6H-V5 Gelonin →IC50 : 100 µg/mL
ISA1-SSPy-Gelonin HA-Cys-V5 →IC50 : 100 µg/mL
ISA1-SSPy-Gelonin HA-Cys-6H  (14 µg/mL) IC50 :10 µg/mL 
ISA1-SSPy efficiently promoted the
intracytoplasmic delivery of gelonin.
20
PAAS AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES
S.C.W. Richardson et al.  Journal of 
Controlled Release 2001, 77, 225–232
ISA1-Gelonin 
↓
IC50 : 522 µg/mL.
ISA1-SSPy promoted the intracytoplasmic
delivery of gelonin more efficiently than
the parent ISA1
21
PAAS AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES
ISA1-SSPy-HA-Cys-6H and ISA1-SSPy-6H-V5 Gelonin showed same results
(IC50:100 µg/mL).
ISA1-SSPy is able to interact with disulfide groups and hydrophobic
domains of the protein, giving stable complexes.
Ricin structure. The A chain (RIP) is shown in
blue and the B chain (cell binding sub-unit) in
orange.
ISA1-SSPy acts as synthetic mimicking of the cell
binding sub-unit of the Ricin toxin that mediates
the internalization of gelonin into the cytosol.
22
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Improvement in drug controlled release is one of the main challenges of modern
pharmacology in order to reduce side effects of therapies and to exploit drug
potential:
 “Solubilization” of lipophilic drugs;
 Specific targeting and release of drugs;
 Sustained release of soluble/insoluble drugs;
 Protection of proteins or genes in transfection.
The use of polymers in designing new drugs architectures, most often in the form
of nanoparticles (NP) is one of the most promising possibilities to achieve these
goals.
24
Using the PAA-SSPy precursors already shown, a family of amphoteric polymers























IC50= 5 mg/ml (B16 cells)
PAA-cholesterol conjugates are able to spontaneously self assemble in
nanoparticles.
Choletserol is an essential structural component of
mammalian cell membranes, where it is required to establish
proper membrane permeability and fluidity.
Yusa, S. I.; Kamachi, M.; Morishima, Y. Macromolecules 2000, 33, 1224–1231.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SPONTANEOUSLY ASSEMBLED PAA-CHOLESTEROL NP
200 nm
Sample % Cholesterol D (nm) PI
ISA1-SSChol1 8 243  16 0.20
ISA1-SSChol2 15 264  21 0.18
ISA23-SSChol1 8 124  6 0.11
ISA23-SSChol2 15 131  7 0.13






The cytotoxicity of PAA-cholesterol conjugates was
assessed by in vitro cytotoxicity assays performed
against 3T3/BALB-c Clone A31 cell lines
D = average diameter.
PI = polydispersity index.
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PAA-CHOLESTEROL NANOPARTICLES








1H NMR OF PAA-CHOLESTEROL CONJUGATES
Ranucci, E.; Suardi, M. A.; Annunziata, R.; Ferruti, P.; Chiellini, F.; Bartoli,C. Biomacromolecules, 2008, 9 (10), 2693-2704
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PAA-CHOLESTEROL NANOPARTICLES
FORMULATION OF DRUG LOADEAD PAA-CHOLESTEROL NP
Electrospray is a method of liquid atomization that
consists in the dispersion of a solution into small
charged droplets by an electric field.
High voltage
15 cm
Doxorubicin loaded (9%) PAA-
cholesterol nanoparticles





Cellular uptake of doxorubicin-loaded and fluorescent PAA-
cholesterol nanoparticles with confocal laser scanning microscopy.
After 1 hour the nanoparticles were internalized in the cells.




FORMULATION OF DRUG LOADEAD PAA-CHOLESTEROL NP
SOLVENT INJECTION METHOD
PAA-cholesterol nanoparticles were formulated by the solvent injection method from
water-ethanol mixtures.
The nanoparticles showed no hemolytic activity tested on in vitro red blood cell.
Sample D (nm) PI PZ (mV)
ISA23-SSChol 60  10 0.26 -14.86  0.99
D = average diameter.
PI = polydispersity index.
PZ = zeta potential
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Unsubstituted β-cyclodextrin (β-CD) is poorly soluble in water and often gives

































































Water solubility 1.85 (g/100 mL)
Cavity volume 262 Å
[a]D 25°c 162.5 + 0.5
pKa 12.2
Many chemical modifications have been proposed for increasing the solubility of
β-CD and its complexes in aqueous media but only relatively few examples of β-
CD conjugates with biocompatible hydrophilic synthetic polymers can be found in
literature.
Szejtli, J. Chem.Rev. 1998, 98, 1743. 
Salmaso, S.; Semenzato, A.; Calicetti, P.; Hoebeke, J.; Sonico, F.; Dubernet, C.; Couvreur, P. Bioconjugate Chem. 2004, 15, 997.
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PAA-b-CYCLODEXTRIN NANOPARTICLES
b-CD-PAA copolymers can be obtained as hyperbranched soluble products, or as
crosslinked nanoparticulated products.
In water at 20-25°C and pH ≥ 11, approximately 5 hydroxyl groups per b-CD molecule
undergo Michael-type addition to bis-acrylamides.























































































































































































































































































Kinetic control Stoichiometric control












1  f  2 
r = ratio between the number of functions of the multifunctional monomer
and the total number of the same functions
f = number of functions of the multifunctional monomer
r = starting ratio among the complementary functions (“a” and “b”)
pc = reaction conversion degree at which gelling takes place;




HIGH PRESSURE HOMOGENIZATION (HPH)
High pressure homogenizer
Particles rupture in precision gap 
during HPH process
PAA micro- and nanogels are obtained by high
pressure homogeneization of hydrogel suspensions.
Procedure:
1) mechanical grinding at 12000 rpm










































Preliminary biological evaluations carried out for
hyperbranched PAA-b-CD including In-vitro MCF-
7 cell viability tests and In-vivo haemolytic
activity (human RBC), have confirmed the















































































































































































































Paclitaxel /PAA- b-CD complex
before lyophilization.
Paclitaxel /PAA- b-CD complex after 
lyophilization.
300 nm
PAA-b-CD can be loaded with Paclitaxel up to 5% of their own weight forming











Paclitaxel even complexed by the polymeric system, mainteins its efficiency in the







5 µm 5 µm
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PAAs constitute a very versatile family of ionic polymers that are easily
synthesized and can be designed to be biocompatible and degradable in the
body fluids.
They warrant potential, inter alia, as intracytoplasmic delivery vehicles of
protein, as nanoparticoles for the release of lipophilic durgs and many other
applications in the nanomedicine filed.
As a final observation, the unique combination of biotechnologically relevant
properties of PAAs are still waiting to be fully exploited.
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